Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
By
[email protected] (James Brumley)
1d agoen
Source
BarsOver 2 Billion Reasons to Love CRISPR Therapeutics Right Nowfool.comThere's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.
You might also wanna read
CRISPR’s next act: the companies editing the epigenome to treat disease
go.nature.com·7d ago
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
bioprocessintl.com·22d ago
STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned
STAT·2d ago
Investing in Longevity: The Complexities of Aging
Investors are heavily investing in longevity-focused biotech companies, with $8.5B deployed in 2024. The complexity of aging involves multip
librariesforthefuture.bio·1y ago
Towards mRNA therapeutics 2.0
doi.org·3d ago
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in can
medium.com·24d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.